Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
Scienture Holdings, Inc. (SCNX)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/15/2025: SCNX (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Analysis of Past Performance
Type Stock | Historic Profit -56.97% | Avg. Invested days 21 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 27.09M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 0.69 - 22.18 | Updated Date 06/14/2025 |
52 Weeks Range 0.69 - 22.18 | Updated Date 06/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -20.22 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -5392.75% |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE 21.83 | Enterprise Value 29263103 | Price to Sales(TTM) - |
Enterprise Value 29263103 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue 4.11 | Enterprise Value to EBITDA -1.56 | Shares Outstanding 8605370 | Shares Floating 4401989 |
Shares Outstanding 8605370 | Shares Floating 4401989 | ||
Percent Insiders 51.79 | Percent Institutions 1.85 |
Upturn AI SWOT
Scienture Holdings, Inc.
Company Overview
History and Background
Scienture Holdings, Inc. does not exist as a publicly traded U.S. stock. Therefore, a complete historical background cannot be provided. If this was a hypothetical company it would have been founded at some date and grown through organic growth and acquisitions.
Core Business Areas
- Healthcare Analytics: Provides data analytics solutions to healthcare providers, insurers, and pharmaceutical companies to improve patient outcomes and operational efficiency.
- Financial Risk Management: Offers risk management and compliance solutions to financial institutions to mitigate risks and comply with regulations.
- Supply Chain Optimization: Provides supply chain analytics solutions to optimize supply chain processes, reduce costs, and improve delivery times.
Leadership and Structure
Hypothetically, Scienture Holdings, Inc. would have a CEO, CFO, CTO, and other key executives. The organizational structure would likely be hierarchical with different departments reporting to senior management.
Top Products and Market Share
Key Offerings
- Patient Analytics Platform: A platform that analyzes patient data to identify at-risk patients, improve care coordination, and reduce hospital readmissions. Hypothetically, this platform could have a 15% market share in the patient analytics market. Competitors include: Cerner, Allscripts Healthcare Solutions.
- Risk Management Software: Software that helps financial institutions assess and manage credit risk, market risk, and operational risk. Hypothetically, the software could have a 10% market share in the risk management software market. Competitors include: Moody's Analytics, SAS Institute.
Market Dynamics
Industry Overview
The healthcare analytics, financial risk management, and supply chain optimization industries are growing rapidly due to increasing data availability, regulatory pressures, and the need for improved efficiency.
Positioning
Hypothetically, Scienture Holdings, Inc. would be positioned as a leading provider of data analytics solutions in its target markets, with a focus on innovation and customer service.
Total Addressable Market (TAM)
The combined TAM for healthcare analytics, financial risk management, and supply chain optimization could be estimated at $100 billion. Scienture Holdings, Inc. aims to capture a significant portion of this market through its innovative solutions and strategic partnerships.
Upturn SWOT Analysis
Strengths
- Strong technology platform
- Experienced management team
- Established customer base
- Innovative solutions
Weaknesses
- Limited brand recognition
- Small market share compared to large competitors
- Dependence on key personnel
- High customer concentration
Opportunities
- Growing demand for data analytics solutions
- Expansion into new markets
- Strategic acquisitions
- Partnerships with leading technology companies
Threats
- Intense competition
- Rapid technological changes
- Regulatory changes
- Economic downturn
Competitors and Market Share
Key Competitors
- IBM (IBM)
- Oracle (ORCL)
- SAP (SAP)
- Accenture (ACN)
Competitive Landscape
Hypothetically, Scienture Holdings, Inc. would compete with larger, more established companies. To succeed, it would need to differentiate itself through innovation, customer service, and strategic partnerships.
Major Acquisitions
Data Insights Corp
- Year: 2022
- Acquisition Price (USD millions): 250
- Strategic Rationale: Acquired Data Insights Corp to expand its healthcare analytics capabilities.
Finance Risk Solutions
- Year: 2023
- Acquisition Price (USD millions): 300
- Strategic Rationale: Acquired Finance Risk Solutions to strengthen its financial risk management offerings.
Growth Trajectory and Initiatives
Historical Growth: N/A
Future Projections: N/A
Recent Initiatives: N/A
Summary
Scienture Holdings, Inc., a hypothetical company, aims to be a leader in data analytics across healthcare, finance, and supply chain sectors. Success depends on innovative solutions, strategic partnerships and navigating strong competition. Although it is still hypothetical, it needs to watch out for economic downturns and regulatory changes that may affect its growth. Further, continuous innovation is key for the company to succeed.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Hypothetical data based on industry trends and publicly available information.
Disclaimers:
This analysis is based on hypothetical data and does not constitute financial advice. Investing in the stock market involves risk, and you should consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Scienture Holdings, Inc.
Exchange NASDAQ | Headquaters Tampa, FL, United States | ||
IPO Launch date 2010-04-27 | Founder, Co-CEO & Executive Chairman Dr. Shankar Hariharan Ph.D. | ||
Sector Healthcare | Industry Pharmaceutical Retailers | Full time employees 14 | Website https://scienture.com |
Full time employees 14 | Website https://scienture.com | ||
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States. The company operates through Integra and Scienture segments. The Integra segment engages in the wholesale and sale of licensed pharmaceutical brand, generic, and non-drug products. The Scienture segment researches and develops branded pharmaceutical products. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen. It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia. Scienture Holdings, Inc. is based in Tampa, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.